Literature DB >> 33643734

Cauda Equina Syndrome as the Initial Presentation of Concurrent Plasmacytoma and Multiple Myeloma.

Alexandra Pisklakova1, Christian Almanzar1, Jan-Paul Sambataro1, Omar Ansari1, Faiza Manji1.   

Abstract

Multiple myeloma is a hematological malignancy characterized by an abnormal proliferation of monoclonal plasma cells. In some occurrences, plasma cell proliferation results in a solitary lesion (solitary bone plasmacytoma or extramedullary plasmacytoma with minimal bone marrow involvement). Approximately 50% of patients with solitary plasmacytoma develop multiple myeloma within 10 years after the initial diagnosis. While back pain and compression fractures are commonly described presentations of multiple myeloma and plasmacytoma, cauda equina syndrome related to plasma cell infiltration is rare and clinical guidelines are limited. Herein, we present a rare case of a woman with acute cauda equina syndrome (CES) secondary to solitary bone plasmacytoma and multiple myeloma.
Copyright © 2021, Pisklakova et al.

Entities:  

Keywords:  back pain; cauda equina syndrome; multiple myeloma; plasmacytoma; spinal cord injury

Year:  2021        PMID: 33643734      PMCID: PMC7901714          DOI: 10.7759/cureus.12888

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  10 in total

1.  High dose therapy with autologous stem cell transplantation for solitary bone plasmacytoma complicated by local relapse or isolated distant recurrence.

Authors:  Meletios A Dimopoulos; Christos Papadimitriou; Athanassios Anagnostopoulos; Dimitrios Mitsibounas; Jean-Paul Fermand
Journal:  Leuk Lymphoma       Date:  2003-01

2.  Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma.

Authors:  Richard Soutar; Helen Lucraft; Graham Jackson; Anthony Reece; Jenny Bird; Eric Low; Diana Samson
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

3.  Solitary plasmacytoma of the thoracic vertebra presenting with sudden paraplegia and back pain: a pathologic case report.

Authors:  Tadashi Terada
Journal:  Pathol Oncol Res       Date:  2010-07-30       Impact factor: 3.201

4.  Head and neck manifestations of plasma cell neoplasms.

Authors:  Y C Nofsinger; N Mirza; P T Rowan; D Lanza; G Weinstein
Journal:  Laryngoscope       Date:  1997-06       Impact factor: 3.325

5.  Solitary bone plasmacytoma compression injury disguised as back pain: a case report.

Authors:  Steven D Jackson; Bethany A Wiering; Amanda A Herrmann; MacKenna A Hinz; Leah R Hanson
Journal:  Spinal Cord Ser Cases       Date:  2019-02-11

Review 6.  Solitary plasmacytoma of bone and asymptomatic multiple myeloma.

Authors:  M A Dimopoulos; L A Moulopoulos; A Maniatis; R Alexanian
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

Review 7.  Red flags to screen for malignancy in patients with low-back pain.

Authors:  Nicholas Henschke; Christopher G Maher; Raymond W J G Ostelo; Henrica C W de Vet; Petra Macaskill; Les Irwig
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

Review 9.  Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Authors:  J Caers; B Paiva; E Zamagni; X Leleu; J Bladé; S Y Kristinsson; C Touzeau; N Abildgaard; E Terpos; R Heusschen; E Ocio; M Delforge; O Sezer; M Beksac; H Ludwig; G Merlini; P Moreau; S Zweegman; M Engelhardt; L Rosiñol
Journal:  J Hematol Oncol       Date:  2018-01-16       Impact factor: 17.388

Review 10.  Multiple myeloma current treatment algorithms.

Authors:  S Vincent Rajkumar; Shaji Kumar
Journal:  Blood Cancer J       Date:  2020-09-28       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.